LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1314
- Registration Number
- NCT00805194
- Locations
- 🇧🇾
Brest Regional Clinical, Brest Region, Belarus
🇦🇹KH St. Vinzenz, Zams, Int. Abtlg., Kufstein, Austria
🇧🇬Specialized Hospital for Active Treatment in Oncolcogy, Sofia, Bulgaria
First Presentation of Parkinson Disease Patients to Neurologist
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2448
- Registration Number
- NCT00802178
- Locations
- 🇸🇮
Boehringer ingelheim Investigational Site 2, Maribor, Slovenia
🇸🇮Boehringer ingelheim Investigational Site 3, Maribor, Slovenia
🇷🇴Boehringer Ingelheim Investigational Site 8, Bucuresti, Romania
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 46
- Registration Number
- NCT00801294
- Locations
- 🇫🇷
1239.2.3301D Hôpital Saint Antoine, Paris Cedex 12, France
🇫🇷1239.2.3301G Hôpital Saint Antoine, Paris Cedex 12, France
🇫🇷1239.2.3301H Hôpital Saint Antoine, Paris Cedex 12, France
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT00800683
- Locations
- 🇺🇸
1218.43.10013 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
🇺🇸1218.43.10009 Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States
🇺🇸1218.43.10018 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 857
- Registration Number
- NCT00798161
- Locations
- 🇨🇦
1218.46.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1218.46.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇨🇦1218.46.11006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
- Conditions
- Bladder, Neurogenic
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 231
- Registration Number
- NCT00796614
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT00796549
- Locations
- 🇮🇹
1200.40.39008 Boehringer Ingelheim Investigational Site, Modena, Italy
🇮🇹1200.40.39005 Boehringer Ingelheim Investigational Site, Monza (MI), Italy
🇮🇹1200.40.39011 Boehringer Ingelheim Investigational Site, Arezzo, Italy
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 937
- Registration Number
- NCT00796653
- Locations
- 🇨🇦
1222.14.4007 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada
🇩🇪1222.14.4103 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇮🇹1222.14.4301 Boehringer Ingelheim Investigational Site, Cassano Delle Murge (ba), Italy
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 906
- Registration Number
- NCT00793624
- Locations
- 🇫🇮
1222.13.2101 Boehringer Ingelheim Investigational Site, Tampere, Finland
🇲🇾1222.13.3102 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia
🇫🇮1222.13.2102 Boehringer Ingelheim Investigational Site, Turku, Finland
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00793793
- Locations
- 🇺🇸
1220.2.10 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸1220.2.15 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸1220.2.17 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States